Aniridia Cell Models for Research

Aniridia is a rare congenital panocular disorder with an estimated global incidence of 1 in 50,000 to 1 in 100,000 live births (Orphanet, 2023). It is caused by heterozygous loss-of-function variants in the PAX6 gene (11p13) and is characterized by complete or partial absence of the iris, foveal hypoplasia, corneal pannus, cataract, and glaucoma. Approximately two-thirds of cases are familial (autosomal dominant), while one-third are sporadic. The clinical impact is severe: up to 50% of patients develop glaucoma, and many progress to corneal opacification and blindness. Aniridia is also a key feature of WAGR syndrome (Wilms tumor, Aniridia, Genitourinary anomalies, mental Retardation), caused by contiguous gene deletions at 11p13 that include PAX6 and WT1. According to the National Cancer Institute (NCI), individuals with WAGR syndrome have a 45-60% lifetime risk of Wilms tumor, necessitating regular surveillance. There is no cure for aniridia; management is symptomatic and includes glaucoma drainage devices, corneal transplantation, and low-vision rehabilitation. The economic burden is substantial due to lifelong ophthalmological care and lost productivity. Research into PAX6 function and aniridia pathogenesis is critical for developing targeted therapies, including gene editing and cell-based interventions.

Aniridia is an ideal model for studying ocular development, gene regulation, and cell fate determination because PAX6 is a master regulator of eye morphogenesis. Key research advantages include:

• • Well-defined genetic cause: PAX6 haploinsufficiency is the primary driver, enabling precise genetic modeling.
• • Public datasets: NCBI Gene (PAX6 ID: 5080), ClinVar (over 1,000 PAX6 variants), and the Human Gene Mutation Database (HGMD) provide rich variant information.
• • Open questions: How do different PAX6 mutations lead to variable phenotypes? What are the molecular mechanisms of corneal limbal stem cell deficiency? Can PAX6 dosage be restored therapeutically?
• • Subtypes: Aniridia can be isolated or syndromic (WAGR), offering distinct research avenues.
• • Relevance to other diseases: PAX6 mutations are also linked to Peters anomaly, foveal hypoplasia, and optic nerve hypoplasia, broadening impact.

These features make aniridia a valuable disease for functional genomics, drug discovery, and precision medicine approaches.

While aniridia is not a cancer, PAX6 dysfunction intersects with pathways relevant to cell proliferation, differentiation, and survival. Key pathways include:

1. PAX6-mediated transcriptional regulation:

• • PAX6 acts as a transcription factor with a paired domain and homeodomain.
• • It regulates genes involved in eye development (e.g., SIX3, OTX2, SOX2) and corneal epithelial homeostasis.
• • Haploinsufficiency disrupts dosage-sensitive targets, leading to developmental defects.

2. Wnt/β-catenin signaling:

• • PAX6 interacts with Wnt pathway components to control limbal stem cell proliferation.
• • Dysregulation contributes to corneal pannus and conjunctivalization.

3. Notch signaling:

• • PAX6 regulates Notch ligands (e.g., DLL1) in the developing retina.
• • Altered Notch activity affects retinal progenitor differentiation and foveal development.

4. TGF-β signaling:

• • PAX6 modulates TGF-β-induced epithelial-mesenchymal transition (EMT) in corneal cells.
• • Aberrant TGF-β activity is linked to corneal fibrosis in aniridia.

These pathways are not classically carcinogenic but are critical for tissue homeostasis and are being explored in regenerative medicine.

The table below summarizes key genetic alterations in aniridia and related disorders, based on ClinVar, COSMIC, and published literature.

Note: PAX6 mutation frequencies are derived from ClinVar (accessed 2024) and HGMD. WT1 deletion frequency is based on WAGR syndrome cohorts.

PAX6 haploinsufficiency leads to widespread transcriptional dysregulation. Key nodes and networks include:

• • PAX6 target genes:
• • Downregulated: SIX3, OTX2, SOX2, CRYAA, CRYAB, PAX6 itself (autoregulation).
• • Upregulated: TGFB1, TGFB2, COL1A1, COL4A1 (fibrosis markers).
• • Wnt/β-catenin network:
• • β-catenin (CTNNB1) accumulation promotes limbal stem cell exhaustion.
• • LEF1/TCF7L2 transcription factors mediate target gene activation.
• • Notch network:
• • Reduced DLL1 and NOTCH1 expression impairs retinal progenitor differentiation.
• • HES1 and HEY1 downstream effectors are downregulated.
• • TGF-β network:
• • SMAD2/3 phosphorylation drives EMT.
• • Increased α-SMA (ACTA2) and fibronectin (FN1) expression.
• • Apoptosis and stress response:
• • TP53 and CDKN1A (p21) may be activated in response to cellular stress.
• • BCL2 family members modulate survival.

These networks are being dissected using gene-edited cell models to identify therapeutic targets.

Several cell lines and organoid models are used to study aniridia. The table below lists commonly used models.

Organoid advantages: 3D structure recapitulates corneal epithelial stratification, stem cell niche, and cell-cell interactions. They enable long-term culture and drug testing. Patient-derived organoids preserve the genetic background, while CRISPR-edited organoids provide isogenic controls.

Animal models are essential for understanding PAX6 function in vivo. Examples include:

• • Pax6 knockout mouse (Pax6-/-): lethal, no eyes; used to study early eye development.
• • Pax6 heterozygous mouse (Pax6+/-): small eyes, iris hypoplasia, corneal abnormalities; mimics aniridia.
• • Small eye (Sey) mouse: spontaneous Pax6 mutation; classic model for aniridia.
• • Zebrafish pax6a/pax6b mutants: rapid screening for eye phenotypes.
• • Xenopus tropicalis pax6 knockout: studies of eye field specification.
• • Induced models: CRISPR-mediated PAX6 knockout in rabbit or primate models for preclinical testing.
• • Patient-derived xenografts (PDX): not applicable for aniridia (non-cancerous), but patient-derived cells can be xenografted for stem cell studies.

These models help validate gene editing strategies and drug candidates.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise PAX6 mutations, providing powerful tools for mechanistic and therapeutic research. Examples include:

• • PAX6 knockout lines: generated in human iPSCs or corneal epithelial cells using CRISPR; used to study loss-of-function phenotypes.
• • PAX6 knock-in lines: introduction of patient-specific mutations (e.g., p.Arg44Ter, p.Gln178Ter) to model genotype-phenotype correlations.
• • PAX6 reporter lines: knock-in of fluorescent reporters (e.g., GFP) under the PAX6 promoter to track expression and screen for modulators.
• • Isogenic pairs: wild-type and mutant lines from the same parental cell line, controlling for genetic background.

Commercially available, sequence-verified gene-edited cell models accelerate research by eliminating the need for in-house editing. These models are quality-controlled for off-target effects and karyotype stability. They are compatible with high-throughput screening, functional genomics, and drug discovery workflows. Researchers can obtain custom gene-edited cell lines tailored to specific PAX6 variants or pathways.

Gene-edited cell models enable systematic interrogation of PAX6 function and its target networks. Applications include:

• • CRISPR knockout screens: identify genes that modify PAX6 haploinsufficiency phenotypes.
• • CRISPR activation (CRISPRa) screens: upregulate PAX6 or compensatory genes to rescue defects.
• • Base editing and prime editing: introduce precise point mutations to model missense variants.
• • Transcriptomic profiling (RNA-seq): compare wild-type and mutant lines to identify differentially expressed genes and pathways.
• • Epigenomic profiling (ATAC-seq, ChIP-seq): map PAX6 binding sites and chromatin accessibility changes.

These approaches validate candidate genes and reveal novel therapeutic targets.

Isogenic PAX6 wild-type and knockout cell lines are ideal for drug screening. Key applications:

• • High-throughput screening: test small molecule libraries for compounds that rescue PAX6-dependent phenotypes (e.g., corneal epithelial differentiation).
• • Resistance modeling: generate PAX6 mutant lines resistant to standard therapies (e.g., glaucoma medications) to identify bypass pathways.
• • Combination therapy: screen for synergistic drug pairs that target deregulated pathways (e.g., Wnt and TGF-β inhibitors).
• • Toxicity testing: assess drug effects on normal vs. PAX6-deficient corneal cells to predict adverse outcomes.

These screens accelerate preclinical development of aniridia therapies.

CRISPR-based synthetic lethality screens in PAX6-mutant cells can uncover biomarkers and therapeutic vulnerabilities. Approaches include:

• • Genome-wide CRISPR knockout screens: identify genes essential for survival of PAX6-haploinsufficient cells but not wild-type cells.
• • RNAi screens: validate synthetic lethal interactions.
• • Proteomics: mass spectrometry to identify PAX6-interacting proteins and downstream effectors.
• • Liquid biopsy: detect PAX6 mutations or downstream biomarkers in tear fluid or blood for non-invasive diagnosis.

These efforts aim to develop companion diagnostics and targeted therapies.

The following databases provide valuable data for aniridia research.